Drug intelligence / Profile preview

VacV000

Development stage: Preclinical
Lead developer: VacV Biotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

**VacV000** is a investigational drug candidate from VacV Biotherapeutics, likely an oncolytic vaccinia virus (VacV) therapy engineered for cancer treatment. It represents a preclinical-stage agent targeting **neoplasms** and **digestive system cancers**, leveraging viral replication in tumor cells to induce immunogenic cell death, stimulate anti-tumor immunity, and potentially synergize with checkpoint inhibitors. No specific mechanism details, indications, or clinical data are publicly available, suggesting early discovery or preclinical development focused on tumor-selective viral oncolysis.[11]

Beyond the preview

Go deeper on VacV000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VacV000.

Explore the full profile